Zobrazeno 1 - 10
of 90
pro vyhledávání: '"JCV Antibody"'
Autor:
Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, Shavy Makh, Sourav Santra, Christophe Hotermans, Lily Lee
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year
Externí odkaz:
https://doaj.org/article/0a6e2137e27b4e0ea304899ccd3fcf9a
Autor:
Harald Hegen, Janette Walde, Gabriel Bsteh, Michael Auer, Sebastian Wurth, Anne Zinganell, Franziska Di Pauli, Florian Deisenhammer, Thomas Berger
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Background: Risk of natalizumab-related progressive multifocal leukoencephalopathy is associated with the presence of anti-JC-virus (JCV) antibodies.Objective: To investigate the impact of disease-modifying treatments (DMT) on the longitudinal evolut
Externí odkaz:
https://doaj.org/article/4570284a220d482884375444af61fca2
Autor:
Steven L. Galetta, Roumen Balabanov, Danette Rutledge, Roger Chang, Ray Su, Denise Campagnolo, Lily Lee, Laura J. Balcer, Jai Perumal, Robin Avila, Robert J. Fox
Publikováno v:
Advances in Therapy
Introduction STRIVE was a 4-year, multicenter, observational, open-label, single-arm study of natalizumab treatment in anti-JC virus antibody-negative (JCV-negative) relapsing-remitting multiple sclerosis (RRMS) patients with disease duration ≤ 3 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::150c4d3589527c233f314a191e9be604
https://doi.org/10.1007/s12325-021-01722-w
https://doi.org/10.1007/s12325-021-01722-w
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Objective To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. Methods Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e4d7c9c6031a5f34b08f44b76b559d6
http://europepmc.org/articles/PMC7522834
http://europepmc.org/articles/PMC7522834
Autor:
Roumen Balabanov, Christophe Hotermans, Steven L. Galetta, Shavy Makh, Jai Perumal, Robert J. Fox, Laura J. Balcer, Lily Lee, Sourav Santra
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Neurology
BMC Neurology
Background STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75d36f27d8cb33afe86e71ad228d6408
http://link.springer.com/article/10.1186/s12883-019-1337-z
http://link.springer.com/article/10.1186/s12883-019-1337-z
Autor:
Véronique Petit, Anna Litwin, Konrad Rejdak, Anna Karbicka, Maciej Maciejowski, Radosław Zajdel, Robert Jałowiński, Wojciech Guenter, Robert Bonek
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 12
Journal of Clinical Medicine, Vol 9, Iss 3867, p 3867 (2020)
Volume 9
Issue 12
Journal of Clinical Medicine, Vol 9, Iss 3867, p 3867 (2020)
Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4534abefd7992a8874554c0f1ae090e
Autor:
Bastian Tugemann
Publikováno v:
Neurology. 95(11)
With great interest I read the article by Schwab et al.1 on the risk of natalizumab-associated progressive multifocal leukoencephalopathy (PML) as a function of CD62L-expression. However, for the statistical analyses, unlike in earlier studies,2,3 th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1bcb235b004460c64d9f3d2ad612a2c
https://pubmed.ncbi.nlm.nih.gov/32934158
https://pubmed.ncbi.nlm.nih.gov/32934158
Autor:
Sandrine Wiertlewski
Publikováno v:
Revue Neurologique. 173:610-613
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491641d10767c184516b78262e2af7be
https://doi.org/10.1016/j.neurol.2017.06.004
https://doi.org/10.1016/j.neurol.2017.06.004
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 2:345-361
Introduction: Precision medicine is an approach to disease prevention and treatment that takes into account individual variability in terms of genetics, environment and lifestyle. This approach depends on clinical, imaging and biological markers to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7694519e79eaf599e5e431d5b321e8b6
https://doi.org/10.1080/23808993.2017.1393315
https://doi.org/10.1080/23808993.2017.1393315
Publikováno v:
Neurology. 92(3)
Berger et al.,1 based on the Novartis safety data lock point of August 31, 2017, reported that the risk of patients developing progressive multifocal leukoencephalopathy (PML) after treatment with fingolimod remains low. Addressing the question of PM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::090addeec1811625fcab4e0532abc16c
https://pubmed.ncbi.nlm.nih.gov/30643034
https://pubmed.ncbi.nlm.nih.gov/30643034